Center for Infectious Disease Research and Policy

IDENTIFYSENSORS BIOLOGICS NAMES GLOBAL SALES DIRECTOR FOR NEW DIGITAL DIAGNOSTIC DEVICE PLATFORM

Retrieved on: 
Tuesday, September 12, 2023
Minnesota Center for Book Arts, DNA, University, Marketing, Policy, COVID-19, Diarrhea, MBA, RNA, COVID-19 testing, Sale, Center for Infectious Disease Research and Policy, Mathieson, Vertically transmitted infection, Research, Notre Dame, FDA, Management, Vaccine

CLEVELAND, Sept. 12, 2023 /PRNewswire/ -- IdentifySensors Biologics, a leading developer of digital diagnostic technologies, has named Mark Mathieson director of global sales operations.

Key Points: 
  • CLEVELAND, Sept. 12, 2023 /PRNewswire/ -- IdentifySensors Biologics, a leading developer of digital diagnostic technologies, has named Mark Mathieson director of global sales operations.
  • Mathieson joins the company with more than 20 years of experience launching, marketing and selling diagnostic systems for some of the largest brands in the world.
  • Devices for the new diagnostic platform began pilot production last month and will be used in clinical evaluations this fall.
  • This platform and its many elements are fully patented, and not yet approved for sale in the United States or other international markets.

University of Missouri Laboratory for Infectious Disease Study Finds Technology Used in Widely Deployed Fingerprint Scanners Kills The Virus that Causes COVID-19

Retrieved on: 
Tuesday, May 9, 2023
Electroluminescence, United Nations, University, CBP, Atmosphere, SARS-CoV-2, Public, LES, Coronavirus, University of Missouri, COVID-19, Airport, Infection, EL, DRS, Biometrics, LIDR, CLEAR, Center for Infectious Disease Research and Policy, Public Facilities Privacy & Security Act, United States Customs Service, Risk, International Red Cross and Red Crescent Movement, Disinfectant, Safety, Medical imaging

COLUMBIA, Mo., May 9, 2023 /PRNewswire/ -- Researchers at the University of Missouri Laboratory for Infectious Disease Research (LIDR) today released the results of a study indicating that electroluminescent (EL) film technology, found in widely deployed biometric fingerprint scanners, actively kills SARS-CoV-2 (coronavirus). Biometric fingerprint scanners are used for identification at borders, airports, arenas, and other public facilities. The study, conducted by Drs. Paul Anderson and Jeffrey Whyte at the University of Missouri Laboratory for Infectious Disease Research, should help to alleviate public fear of contracting COVID-19 via fingerprint scanners. 

Key Points: 
  • COLUMBIA, Mo., May 9, 2023 /PRNewswire/ -- Researchers at the University of Missouri Laboratory for Infectious Disease Research (LIDR) today released the results of a study indicating that electroluminescent (EL) film technology, found in widely deployed biometric fingerprint scanners, actively kills SARS-CoV-2 (coronavirus).
  • Biometric fingerprint scanners are used for identification at borders, airports, arenas, and other public facilities.
  • Paul Anderson and Jeffrey Whyte at the University of Missouri Laboratory for Infectious Disease Research, should help to alleviate public fear of contracting COVID-19 via fingerprint scanners.
  • The University of Missouri study, which examined transmission of live samples of SARS-CoV-2, revealed that the EL-based technology used in fingerprint scanners actively kills the coronavirus through the electric field created during the collection process.

CGTN: New Approaches: Why China is easing its COVID-19 curbs now

Retrieved on: 
Tuesday, December 20, 2022
Death, World Health Organization, Vaccination, Severe acute respiratory syndrome coronavirus 2, Nature, Patient, Mutation, Respiratory disease, Laboratory, Hainan Medical University, Science Advances, COVID, National Institutes of Health, Routing protocol, Disease, University, Hong Kong residents, Alpha, COVID-19, Chinese Center for Disease Control and Prevention, Infection, Social mobility, Center for Infectious Disease Research and Policy, Virology, Mouse, Fudan University, Diagnosis, Economic development, Gamma, Sun, National Health Commission, Ageing, Virulence, Huashan Hospital, Animal, Pharmaceutical industry, Vaccine, Delta, Omicron

By November when China announced its new policies to relax a series of stringent measures meant to monitor and cut the spread of COVID-19, the country had reported over 5,000 deaths caused by this virus.

Key Points: 
  • By November when China announced its new policies to relax a series of stringent measures meant to monitor and cut the spread of COVID-19, the country had reported over 5,000 deaths caused by this virus.
  • The low death toll, out of a population of 1.4 billion, did not come easily.
  • As many countries tried and gave up stricter measures one after another in the past three years, China didn't follow.
  • Data showed that Omicron replicates to lower levels than the Delta in rhesus macaques, resulting in reduced clinical disease.

CGTN: New Approaches: Why China is easing its COVID-19 curbs now

Retrieved on: 
Tuesday, December 20, 2022
Death, World Health Organization, Vaccination, Severe acute respiratory syndrome coronavirus 2, Nature, Patient, Mutation, Respiratory disease, Laboratory, Hainan Medical University, Science Advances, COVID, National Institutes of Health, Routing protocol, Disease, University, Hong Kong residents, Alpha, COVID-19, Chinese Center for Disease Control and Prevention, Infection, Social mobility, Center for Infectious Disease Research and Policy, Virology, Mouse, Fudan University, Diagnosis, Economic development, Gamma, Sun, National Health Commission, Ageing, Virulence, Huashan Hospital, Animal, Pharmaceutical industry, Vaccine, Delta, Omicron

By November when China announced its new policies to relax a series of stringent measures meant to monitor and cut the spread of COVID-19, the country had reported over 5,000 deaths caused by this virus.

Key Points: 
  • By November when China announced its new policies to relax a series of stringent measures meant to monitor and cut the spread of COVID-19, the country had reported over 5,000 deaths caused by this virus.
  • The low death toll, out of a population of 1.4 billion, did not come easily.
  • As many countries tried and gave up stricter measures one after another in the past three years, China didn't follow.
  • Data showed that Omicron replicates to lower levels than the Delta in rhesus macaques, resulting in reduced clinical disease.

Pilgrim Lutheran Christian School adds a powerful UVC lighting system to their lunchroom.

Retrieved on: 
Wednesday, February 9, 2022
Omicron, School, Center for Infectious Disease Research and Policy, Confidence, Delta, Atmosphere, Student, PLCS, Pilgrim, UVC, Lunch, University, Severe acute respiratory syndrome coronavirus 2, Engineering, Virus, Assurance, Partnership, Clinic, Child, Circadian rhythm, COVID-19, Vaccine

PORTLAND, Ore., Feb. 9, 2022 /PRNewswire/ --UV Health Group, a U.S.-based designer and manufacturer of antimicrobial UVC products, has teamed up with Pilgrim Lutheran Christian School (PLCS) in Beaverton, Oregon to combat airborne viruses in the school's lunchroom, The Pilgrim Caf.

Key Points: 
  • PORTLAND, Ore., Feb. 9, 2022 /PRNewswire/ --UV Health Group, a U.S.-based designer and manufacturer of antimicrobial UVC products, has teamed up with Pilgrim Lutheran Christian School (PLCS) in Beaverton, Oregon to combat airborne viruses in the school's lunchroom, The Pilgrim Caf.
  • "We designed our powerful UVC system to keep room air safe from viruses while people are in the room, especially when they are not wearing masks.
  • The Pilgrim Caf is precisely the type of room where our system is needed and highly effective,"said Steve Daniel, President of UV Health Group.
  • Learn more at www.uvhealthgroup.com or email [email protected]
    Pilgrim Lutheran Christian School is a Pre-K through 8th grade school who seeks to serve with church and home in developing the whole child body, mind, and spirit.

Biom Pharmaceuticals' Antiviral Compound Bi121 Shows Broad-spectrum Activity Against Three Variants of SARS-CoV-2

Retrieved on: 
Thursday, February 3, 2022
Longevity, Infection, Center for Global Infectious Disease Research, Diversity, Neurodegeneration, BioRxiv, Center, Center for Infectious Disease Research and Policy, Probiotic, Death, Technology, Research, Indian Institute of Science, Disease, Health, Timeline of the COVID-19 pandemic, Life, Nutritional science, Severe acute respiratory syndrome coronavirus 2, Biome, Biosafety, Pharmaceutical industry, Dietary supplement, Omicron

An antiviral formulation that has significant antiviral activity against current and future variants of SARS-CoV-2 is a global medical need.

Key Points: 
  • An antiviral formulation that has significant antiviral activity against current and future variants of SARS-CoV-2 is a global medical need.
  • After screening a prospective seventy-three herbal compounds from Biom Pharmaceutical's library, two preparations showed antiviral SARS-CoV-2 activity, of which Bi121 showed broad-spectrum activity.
  • Bi121 showed significant activity towards all three variants tested, in two different cell lines showing a broad-spectrum activity.
  • Biom Probiotics is marketing a dietary supplement that contains Bi121 together with Biom's gut microbiome diversifying prebiotics (Diversify), under the brand Biom D'Fend.

BGS Announces New Indo-Pacific Practice

Retrieved on: 
Friday, December 3, 2021
Research, United States Indo-Pacific Command, Justice minister, Fellow, Technology, Private sector, Directorate of Defense Trade Controls, American Institutes for Research, BGS, CIDRAP, White, INDOPACOM, Beacon Global Strategies, Human, United States Senate Committee on Armed Services, White House, White House Office, Center for Strategic and Budgetary Assessments, Center for Infectious Disease Research and Policy, Commander, Center, Department of Defence, CIA, Defence Intelligence Agency (India), Capitol Hill, United Nations Security Council, American Institute, Central Intelligence Agency, Professional Staff Congress, Human rights, United States Department of State, National Security Council, National, Management

The practice is led by Mr.Eric Sayers, BGS Senior Vice President.

Key Points: 
  • The practice is led by Mr.Eric Sayers, BGS Senior Vice President.
  • Prior to joining BGS, Mr. Sayers was a Special Assistant to the Commander at U.S. Indo-Pacific Command (INDOPACOM).
  • Mr.Ivan Kanapathyrecently joined BGS as a Vice President and will bring his unique expertise and perspective to the Indo-Pacific Practice.
  • "Eric and his team have the expertise that will enable BGS to dramatically expand the services we offer our clients."

CAPRISA and Evotec Launch New Project to Fast-Track New Technology for HIV Prevention

Retrieved on: 
Monday, October 25, 2021
Biotechnology, AIDS, Health, Pharmaceutical, Clinical Trials, Woman, Science, Statistics, Neurology, Research, Biotechnology, AIDS, University, Virology, LinkedIn, Vaccine Research Center, CAPRISA, HIV/AIDS, University of the Western Cape, Ethics, NIH, Human, European Union, Twitter, Patient, Infection, Republic, Machine learning, Molecular epidemiology, Health policy, University of KwaZulu-Natal, Clinical trial, Antibody, VRC, Center, Nelson, National Institute for Communicable Diseases, Evotec, Man, Union, Artificial intelligence, National Institute, Just, Kniphofia, Columbia University, WHO, Therapy, National Institute of Allergy and Infectious Diseases, Center for Infectious Disease Research and Policy, Medical specialty, University of Cape Town, HIV, Vaccine, Pharmaceutical industry, Fine chemical, Evotec, CAPRISA, EVOTEC, CAPRISA

The principal aim of the new joint project is to change the course of the HIV epidemic in Africa, which has 70% of the global HIV burden.

Key Points: 
  • The principal aim of the new joint project is to change the course of the HIV epidemic in Africa, which has 70% of the global HIV burden.
  • The next step is to assess if the antibody can prevent HIV infection in humans as effectively as it does in monkeys.
  • If shown to be effective in preventing HIV, the antibody, in conjunction with the VRCs VRC07 antibody, has the potential to break the HIV infection cycle.
  • Prof Salim Abdool Karim, Director of CAPRISA: We are excited to work with Evotec and the VRC in this project to improve the CAP256 manufacturing processes.

World-renowned public health expert, Dr. Michael T. Osterholm to be featured in Collective[i] Forecast speaker series

Retrieved on: 
Thursday, November 19, 2020
Health, Michael Osterholm, Articles, Deadliest Enemy, Public Health Emergency of International Concern, Center for Infectious Disease Research and Policy, COVID-19 pandemic

Collective[i] Forecast featuring Dr. Michael T. Osterholm will take place November 19, 2020 at 5 P.M. Eastern, and will explore the topic "Defeating our Deadliest Enemy: The Path to Ending the Pandemic."

Key Points: 
  • Collective[i] Forecast featuring Dr. Michael T. Osterholm will take place November 19, 2020 at 5 P.M. Eastern, and will explore the topic "Defeating our Deadliest Enemy: The Path to Ending the Pandemic."
  • During this session, Dr. Osterholm will discuss the evolving reality of the COVID-19 pandemic, and what we can expect from the coming months as we move into 2021.
  • Dr. Osterholm currently serves as Regents Professor and the Director of the Center for Infectious Disease Research and Policy at the University of Minnesota.
  • Collective[i]'s applications and network employ AI/ML to offer the on demand intelligence that is essential to modern sales organizations.

United States Influenza Vaccines Market Review & Forecast; 2013-2019 & 2019-2025

Retrieved on: 
Thursday, September 12, 2019
Medical specialties, RTT, Vaccination, Medicine, Vaccines, Influenza vaccine, Vaccine, Influenza, H5N1 vaccine, Center for Infectious Disease Research and Policy

The report contains a deep analysis of the US influenza vaccines market with size in terms of both value and volume of the US influenza vaccines market.

Key Points: 
  • The report contains a deep analysis of the US influenza vaccines market with size in terms of both value and volume of the US influenza vaccines market.
  • The prominent factors that are expected to contribute to the growth of the US Influenza vaccines market during the forecast period:
    The report provides clear insight into current and future developments of the United States influenza vaccines market.
  • The report also details the latest information about the influenza vaccines production, supply, and allocation by major companies in the United States.
  • A comprehensive analysis has been done on pricing, distribution & demand and effectiveness of the influenza vaccines in the United States.